Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Drugs In Development, 2024 report and make more profitable business decisions.
Familial hypercholesterolemia (FH) is a genetic disorder that affects the way the body processes cholesterol. People with FH have very high levels of low-density lipoprotein (LDL) cholesterol, also known as “bad” cholesterol, in their blood. This can lead to early and severe cardiovascular diseases, such as heart attacks and strokes. FH is caused by a mutation in one or more genes that are involved in removing LDL cholesterol from the blood. The most common gene affected is LDLR, which encodes the LDL receptor protein. Other genes that can cause FH are APOB, PCSK9, and LDLRAP1. FH is inherited in an autosomal dominant pattern, which means that having one copy of the mutated gene is enough to cause the condition. People who inherit two copies of the mutated gene have a more severe form of FH. FH affects about 1 in 250 people worldwide, but the prevalence may vary depending on the population and the genetic background. FH can be diagnosed by measuring the blood cholesterol levels, examining the physical signs of cholesterol deposits (such as xanthomas and arcus corneae), and performing genetic testing to confirm the mutation. FH can be treated with medications that lower cholesterol levels, such as statins, bile acid sequestrants, ezetimibe, and PCSK9 inhibitors. Some people with FH may also need other treatments, such as LDL apheresis or liver transplantation, to reduce their risk of complications. FH also requires lifestyle modifications, such as eating a healthy diet, exercising regularly, avoiding smoking, and managing other risk factors for cardiovascular diseases.
The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) drugs in development market research report provide comprehensive information on the therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 45 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akeso IncAmgen Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Beijing Mabworks Biotech Co Ltd
Chiesi Farmaceutici SpA
Daewoong Pharmaceutical Co Ltd
EDIRNA Inc
EmendoBio Inc
Epicrispr Biotechnologies Inc
Esperion Therapeutics Inc
Gruthan Bioscience LLC
Hanmi Science Co Ltd
iMetabolic Biopharma Corp
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
LIB Therapeutics LLC
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Merck & Co Inc
NeuroBo Pharmaceuticals Inc
NewAmsterdam Pharma Company NV
Novartis AG
Novo Nordisk AS
OrsoBio Inc
PRD Therapeutics Inc
Precision Biosciences Inc
Repair Biotechnologies Inc
Saliogen Therapeutics Inc
San Raffaele Telethon Institute for Gene Therapy
Sanofi
Shanghai Junshi Biosciences Co Ltd
Suzhou Ribo Life Sciences Co Ltd
Tangdu Hospital
Ultragenyx Pharmaceutical Inc
University Hospitals Leuven
Verve Therapeutics Inc
Vesicle Therapeutics Inc
Visirna Therapeutics HK Ltd
Xi'an Jiaotong University
Yaotang (Shanghai) Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions